According to MAP Pharmaceuticals, it has completed a year-long open label safety trial of its Levadex inhaled dihydroergotamine, the final step in its development program for the product. More than 250 patients completed the 12-month study. The company plans to submit an NDA for Levadex in the first half of 2011. Read the company's press release. … [Read more...] about MAP completes final Levadex trial
Medical
Pearl announces positive Phase 2b results for COPD drug
According to Pearl Therapeutics, a Phase 2b study has demonstrated that its PT003 glycopyrrolate/formoterol combination MDI provides superior bronchodilation compared to placebo, compared to its individual components, and compared to tiotropium. The trial involved patients with moderate to very severe COPD. Read the company's press release. … [Read more...] about Pearl announces positive Phase 2b results for COPD drug
Verona announces successful proof of concept tests of lead product
Verona Pharma, which has been looking for a partner for its lead product RPL554, an inhaled phosphodiesterase 3 and phosphodiesterase 4 inhibitor for the treatment of asthma, COPD, and allergic rhinitis, announced that it has performed successful delivery tests by nebulizer, MDI, and DPI. Read the company's press release. … [Read more...] about Verona announces successful proof of concept tests of lead product
New asthma cure — quit Facebook?
An article published in The Lancet on November 20, 2010 describes the case of a teen-aged boy who appeared to suffer from asthma exacerbations linked to emotional distress caused by his use of Facebook. His asthma had previously been well controlled with ICS and Singulair; but after he was dumped by his girlfriend, visits to her profile page coincided with measurable … [Read more...] about New asthma cure — quit Facebook?
Clinicians told they overprescribe combination inhalers
Researchers from the Medco Research Institute presented data at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) showing that clinicians are prescribing ICS/LABA combination treatment for two thirds of patients with mild persistent asthma and that the combination therapy has no benefit for these patients compared to ICS … [Read more...] about Clinicians told they overprescribe combination inhalers
Mannkind announces positive Phase 3 results while facing clinical trial fraud accusations
Having recently announced that it stands by its clinical trials after a former executive filed suit against the company for retaliatory termination after he raised concerns about the validity of studies conducted in Russia and Bulgaria, Mannkind has released new data from a Phase 3 bioequivalence study of its Afrezza inhaled insulin. The new data concern the … [Read more...] about Mannkind announces positive Phase 3 results while facing clinical trial fraud accusations
Teva announces positive Phase 3 results for Qnaze nasal spray
A Phase 3 study of the Qnaze beclamethasone nasal spray from Teva has demonstrated that the product produced significant symptom relief compared to placebo, according to a Teva presentation at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). Qnaze is a "dry" HFA intranasal formulation delivered by MDI and … [Read more...] about Teva announces positive Phase 3 results for Qnaze nasal spray
Bitop initiates trial of Ectoin inhalation solution
German biotech company bitop AG announced that it has begun enrolling patients in a clinical trial of its Ectoin inhalation solution for the treatment of airway inflammation. In addition to the inhalation solution, bitop is also developing an Ectoin nasal spray and and a DPI. According to bitop, Ectoin is a naturally-occurring "cell protection … [Read more...] about Bitop initiates trial of Ectoin inhalation solution
Study shows increased risk of diabetes with ICS use
An article in the November issue of the American Journal of Medicine reports that a study of almost 400,000 COPD and asthma patients showed a 34% increase in the rate of Type 2 diabetes among those using inhaled corticosteroid (ICS). Higher doses of ICS were associated with higher increased risk of developing diabetes. The study was conducted by … [Read more...] about Study shows increased risk of diabetes with ICS use
Disappointing Phase 3 results for aclidinium bromide
Almirall and Forest Laboratories have announced that a Phase 3 study of their aclidinium bromide DPI for the treatment of COPD produced significant improvement from baseline in FEV1 at clinical doses but underperformed when compared to placebo. Another Phase 3 double-blind study is still underway, and Forest Lab's President Lawrence S. Olanoff expressed … [Read more...] about Disappointing Phase 3 results for aclidinium bromide